Kolexia
Montagne Nathalie Médecine interne
Montagne Nathalie
Médecine interne
Centre Hospitalier de Antibes
Antibes, France
41 Activités
494 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndrome d'immunodéficience acquise Sepsie Monosomie Néphrite interstitielle Infections opportunistes liées au SIDA Leishmaniose viscérale Leucémie aigüe myéloïde Démence associée au SIDA Leishmaniose

Collaborateurs

Voir plus
Vassallo Matteo
Vassallo Matteo
Centre Hospitalier de Cannes, Cannes, France
Durant Jacques
Durant Jacques
Hôpital De l'Archet, Nice, France
Denis Eric
Denis Eric
Centre Hospitalier de Antibes, Antibes, France
Etienne Cedric
Etienne Cedric
Centre Hospitalier de Grasse, Grasse, France

Industries

Voir plus
ViiV Healthcare
10 collaboration(s)
Dernière en 2023
MSD
9 collaboration(s)
Dernière en 2023
OVERCOME
3 collaboration(s)
Dernière en 2021
A+A
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Procalcitonin and C-Reactive Protein/Procalcitonin Ratio as Markers of Infection in Patients With Solid Tumors.
Frontiers in medicine   12 mars 2021
Short-course daptomycin lock and systemic therapy for catheter-related bloodstream infections: a retrospective cohort study in cancer patients with surgically implanted devices.
Journal of chemotherapy (Florence, Italy)   25 janvier 2017
Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
HIV medicine   18 mai 2015
Visceral leishmaniasis due to Leishmania infantum with renal involvement in HIV-infected patients.
BMC infectious diseases   30 octobre 2014
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.
Blood cancer journal   01 novembre 2013
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
American journal of hematology   23 juillet 2013
Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.
Blood   16 novembre 2012
Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients
Blood   16 novembre 2012
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}